drugset / Trial / NCT02059564

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT02059564

Phase 1 Unknown 44 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects with Type 2 Diabetes Mellitus

Timeline

Start
2013-12
Primary completion
2014-10
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Efpeglenatide Peptide 6 mg
Subject Efpeglenatide Peptide 16 mg
Subject Liraglutide Peptide 1.8 mg

Indications